GLP-1 and GIP Receptor Agonists: Expanding Role in Cardiovascular-Kidney-Metabolic Health

What the researchers found

Review of GLP-1 and GIP receptor agonists'expanding role covers their guideline-directed use across cardiovascular, kidney, and metabolic conditions with emerging evidence for dual agonism.

Why it matters

These findings have practical implications for the growing number of patients using peptide-based therapies.

The numbers in context

Review covers large clinical outcome trials establishing GLP-1 RAs as guideline-directed therapies for multiple CKM conditions.

How the study worked

Study methodology detailed in the full publication.

Who was studied

Patients with cardiovascular-kidney-metabolic syndrome across major clinical trials

What this study cannot tell us

Study limitations in the full publication.

How to read the evidence

Evidence level based on study design in publication.

When this study was published

Published in 2025.

The bigger picture

This study contributes to the expanding evidence for peptide therapeutics in clinical practice.

Questions still open

• What are the long-term implications?
• How do results compare to other evidence?
• What further research is needed?

Common questions

Read the original research

Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.

Cardiology clinics, 43(3), 415-432

Citation

Alicic, Radica Z; Neumiller, Joshua J. (2025). Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.. Cardiology clinics, 43(3), 415-432. https://doi.org/10.1016/j.ccl.2024.12.003